SUMMER LAWSON: Open Payments
NPI 1245442243 · COLUMBUS, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$874 in 13 payments from 8 companies in 2025. Trend: 2023 $40 · 2024 $424 · 2025 $874
Food & beverage: $862Travel & lodging: $12
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $273 |
| Alkermes, Inc. | 2 | $163 |
| ABBVIE INC. | 2 | $145 |
| Vanda Pharmaceuticals Inc. | 1 | $122 |
| E.R. Squibb & Sons, L.L.C. | 1 | $113 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Merck Sharp & Dohme LLC | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $15 |
Products named: INGREZZA, LYBALVI, VRAYLAR, FANAPT, COBENFY, GVOKE HYPOPEN, PIFELTRO, Auvelity.
Industry payments across OH — which companies pay providers there.
